[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cancer-solid-tumors\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cancer-solid-tumors":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,12,0,[8,48,76,103,133,156,185,212,243,273,304,354],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":30,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100053935","phase-2-steroid-sparing-regimen-with-olanzapine-and-palonosetron-for-emetic-prevention-for-high-dose-cisplatin-100053935",false,"NCT07699276","Steroid Sparing Regimen With Olanzapine and Palonosetron for Emetic Prevention for High Dose Cisplatin","Steroid-sparing Regimen With Olanzapine and Ondansetron to Prevent Emesis Caused by High Dose Cisplatin in Solid Cancer Patient : A Single Arm Phase II Study","Inclusion Criteria:\n\n* histologically confirmed solid malignancy\n* scheduled for first cycle of cisplatin at dosage of at least 50 mg\u002Fm2\n\nExclusion Criteria:\n\n* pregnancy\n* pelvic or abdominal radiation within 4 weeks\n* uncontrolled brain metastasis\n* other moderate or high emetic risk chemotherapy on day 2-5\n* untreated gut obstruction\n* known allergy or severe adverse effect from palonosetron or olanzapine\n* AST\u002F ALT \\> 2.5x or serum creatinine clearance less than 50 ml\u002Fmin","ALL","18 Years",{"count":19,"type":20},95,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","A phase II study evaluating dexamethasone sparing regimen with olanzapine and palonosetron for patients receiving high dose cisplatin to prevent chemotherapy induced nausea and vomiting",[26,27,28,29],"Cancer (Solid Tumors)","Vomiting","Cisplatin","Olanzapine",[31,32,33,34],"cisplatin","chemotherapy induced nausea vomiting","dexamethasone sparing","olanzapine","RECRUITING","2026-07-07",{"date":38,"type":39},"2026-07-13","ACTUAL",{"date":41,"type":39},"2026-02-10",{"date":43,"type":20},"2027-11-15",{"name":45,"class":46},"Mahidol University","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":56,"targetDuration":58,"studyType":59,"phases":4,"briefSummary":60,"conditions":61,"keywords":63,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":47},"100644598","dietary-supplements-among-cancer-patients-tolerance-impact-on-medications-and-potential-drug-interactions-100644598","NCT07670234","Dietary Supplements Among Cancer Patients: Tolerance, Impact on Medications, and Potential Drug Interactions","Use of Dietary Supplements Among Cancer Patients: Tolerance and Impact on Medications and Drug Interactions Assessed Using the Hedrine Software","Dietary Supple","Inclusion Criteria:\n\n* Patients diagnosed with cancer and receiving medical anticancer treatment, including chemotherapy, hormone therapy, immunotherapy, and targeted therapies.\n* Current or recent use of one or more dietary supplements (e.g., vitamins, minerals, herbal products, or other nutritional supplements).\n* Adult patients : \\>=18\n\nExclusion Criteria:\n\n* Patients unable to complete the study questionnaire because of cognitive impairment or a deteriorated health condition.\n* Failure or refusal to provide written informed consent.",{"count":57,"type":20},1000,"1 Day","OBSERVATIONAL","The goal of this observational study is to To assess the prevalence and patterns of dietary supplement use among patients with cancer and to analyze the impact of these supplements in the context of anticancer medical treatments, including chemotherapy, targeted therapies, hormone therapy, and immunotherapies.\n\nThe main questions it aims to answer :\n\n* What is the prevalence of dietary supplement use among cancer patients, and what is their tolerance profile?\n* Are there any potential drug interactions between dietary supplements and anticancer medications?\n\nParticipants will:\n\n* Provide sociodemographic information, including age, sex, educational level, and other relevant characteristics.\n* Report their use of dietary supplements, including the types of supplements consumed (e.g., vitamins, minerals, herbal products), dietary practices, frequency and duration of use, and reasons for consumption (e.g., medical recommendation or self-medication).\n* Report any perceived adverse effects related to dietary supplement use to assess tolerance.\n* Allow the collection of relevant clinical data from their medical records, including cancer type, ongoing anticancer treatments, and treatment-related adverse effects.",[26,62],"Interaction Drug Food",[64,65,66],"dietary supplements","cancer","Anticancer Therapy","2026-06-19",{"date":69,"type":39},"2026-06-26",{"date":71,"type":39},"2025-06-01",{"date":73,"type":20},"2027-12-31",{"name":75,"class":46},"Centre Mohammed VI de la Recherche et de l'Innovation (CM6RI)",{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":4,"eligibilityCriteria":82,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":83,"targetDuration":4,"studyType":21,"phases":85,"briefSummary":86,"conditions":87,"keywords":90,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":101,"locationsCount":47},"100642041","phase-2-sbrt-lattice-pathy-100642041","NCT07645261","SBRT-LATTICE-PATHY","Impact of Partial Stereotactic Body Radiotherapy in Hypoxic Segments of Large-volume Unresectable Tumors (SBRT-LATTICE-PATHY) - a Prospective Phase II Study.","Inclusion Criteria:\n\n* age =or\\> 18 years;\n* Eastern Cooperative Oncology Group (ECOG) performance status \\\u003C 2; benign and malignant tumors for which the use of radiotherapy is well established in the literature;\n* tumors =or\\> 340 cm³ or with a largest diameter =or\\> 7 cm;\n* no indication for any other type of treatment due to lack of proven clinical benefit (surgery, chemotherapy, standard radiotherapy, immunotherapy, targeted therapy, etc.);\n* Palliative Prognostic Index (PPI) =or\\\u003C 2;\n* metastatic disease in the central nervous system (CNS), if present, controlled (up to 3 metastases, each up to 1 cm);\n* up to 5 extracranial distant metastases (nodal or extranodal) =or\\\u003C 5 cm; signed Informed Consent Form (ICF).\n\nExclusion Criteria:\n\n* cases in which tumor volume and\u002For the patient's clinical condition make adequate immobilization\u002Fsimulation impossible;\n* previous local radiotherapy;\n* pregnant patients;\n* autoimmune diseases;\n* genetic instability syndromes;\n* ongoing systemic therapy;\n* renal insufficiency that prevents the use of iodinated contrast.",{"count":84,"type":20},20,[23],"To assess the importance of using SBRT-LATTICE-PATHY for the radiotherapy treatment of large tumors that would be considered intractable by currently used standard techniques. In this present study, the investigators will have the possibility of combining SBRT and LATTICE techniques, incorporating the concept of hypoxic tissue irradiation, which are potential modulators of abscopal and bystander effects, performing partial punctual treatment in the vertex region, without the need for irradiation of the entire tissue volume, further improving safety in relation to possible toxicities.",[88,26,89],"Cancer (Advanced Stage)","Tumor",[91,92,93,94],"SBRT","LATTICE","partial irradiation","large volume tumors","2026-06-08",{"date":97,"type":39},"2026-06-12",{"date":99,"type":39},"2026-04-28",{"date":73,"type":20},{"name":102,"class":46},"University of Sao Paulo General Hospital",{"id":104,"slug":105,"hasResults":11,"nctId":106,"briefTitle":107,"officialTitle":108,"acronym":4,"eligibilityCriteria":109,"healthyVolunteers":11,"sex":16,"minAge":110,"maxAge":4,"enrollmentInfo":111,"targetDuration":4,"studyType":21,"phases":113,"briefSummary":115,"conditions":116,"keywords":118,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":124,"lastUpdatePostDateStruct":125,"startDateStruct":127,"completionDateStruct":129,"leadSponsor":131,"locationsCount":47},"100630227","trtrm-acttop--guided-dosing-strategy-in-older-patients-with-cancer-100630227","NCT07484932","TRTRM (ACTTOP) -Guided Dosing Strategy in Older Patients With Cancer","Clinical Utility of the Treatment-related Toxicity Risk Model (TRTRM\u002F ACTTOP) in Older Patients With Cancer: a Randomised Controlled Trial","Inclusion Criteria:\n\n1. Aged 65 or above\n2. A diagnosis of lung cancer, gastrointestinal cancer, breast cancer, prostate cancer, and uterine cancer with histological confirmation or radiological diagnosis\\*\\*\n3. Seen by the oncologist and scheduled to receive a new systemic anti-cancer treatment, including chemotherapy, targeted therapy, and immunotherapy, in either radical or first\u002Fsecond-line palliative intent. The planned treatment regimen is expected to last for at least 3 months.\n4. ECOG performance status of 0-2\n5. Agreement for treatment according to the TRTRM (ACTTOP) -risk strategy if in the TRTRM (ACTTOP) -informed care group\n6. Fluent in English or Chinese\n7. Valid consent obtained \\*\\* Only these five types of cancer are included to reduce the heterogeneity of the patients, as they are the top 5 cancers in Hong Kong.\n\nExclusion Criteria:\n\n1. Planned for radiotherapy alone\n2. Planned for systemic treatment concomitant with radiotherapy\n3. Scheduled to have hormonal therapy alone e.g. tamoxifen, aromatase inhibitors, luteinizing hormone-releasing hormone agonist (LHRHa)\n4. Planned for surgery within 3 months\n5. Dementia or patient mentally not fit for consent","65 Years",{"count":112,"type":20},400,[114],"NA","Older adults receiving systemic cancer treatments are at increased risk of developing severe treatment-related toxicities (TRT). Existing prediction tools such as CARG and CRASH have limited applicability in Chinese populations and do not fully address toxicities associated with newer therapies, including immunotherapy and targeted agents. The Treatment-related Toxicity Risk Model (TRTRM) was recently developed and validated in Hong Kong using data from 700 older cancer patients and has demonstrated better predictive accuracy and clinical relevance compared with existing tools.\n\nThis multi-center, open-label, randomized controlled trial aims to evaluate the clinical utility of the TRTRM by guiding treatment dose intensity and monitoring strategies. Participants aged 65 years or older who are starting a new systemic anti-cancer treatment will be randomized in a 1:1 ratio to receive either usual care or TRTRM-informed care. In the intervention arm, patients identified as having intermediate or high risk of toxicity will receive a \"start-low, go-slow\" dosing strategy with close monitoring, while low-risk patients will receive standard dosing.\n\nThe primary outcome is the incidence of grade 3 or higher treatment-related toxicities within the first two months of treatment initiation. Secondary outcomes include emergency visits, unplanned hospitalizations, premature treatment termination, early mortality, quality of life, and overall survival.",[26,117],"Geriatric Oncology",[119,120,121,122,123],"toxicities","prediction model","ACTTOP","Older patients","geriatrics","2026-05-16",{"date":126,"type":39},"2026-05-20",{"date":128,"type":39},"2026-05-04",{"date":130,"type":20},"2030-07-31",{"name":132,"class":46},"The University of Hong Kong",{"id":134,"slug":135,"hasResults":11,"nctId":136,"briefTitle":137,"officialTitle":137,"acronym":4,"eligibilityCriteria":138,"healthyVolunteers":139,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":140,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":142,"conditions":143,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":147,"lastUpdatePostDateStruct":148,"startDateStruct":150,"completionDateStruct":152,"leadSponsor":154,"locationsCount":47},"100638678","is-the-1939-cancer-act-fit-for-purpose-in-the-modern-technology-era-100638678","NCT07584824","Is the 1939 Cancer Act Fit for Purpose in the Modern Technology Era?","Inclusion Criteria:\n\nPatients\u002FRelatives:\n\n* UK residents (England and Wales ONLY).\n* Have been treated for a cancer within the last three years.\n* Aged 18 or over.\n* Can complete the survey themselves or have it completed on their behalf by a friend or family member (with the patient's permission).\n\nHealthcare Professionals:\n\n* UK-based professionals in the healthcare industry.\n* Working with patients diagnosed with cancer.\n* Consulting with patients at least once a month or more frequently.\n* Aged 18 or over.\n\nExclusion Criteria:\n\nNo explicit exclusion criteria are defined within provided materials, therefore any individual not meeting the inclusion criteria will be excluded.",true,{"count":141,"type":20},50,"The 1939 Cancer Act in the UK (England \\& Wales) prohibits advertising of cancer treatments to the public, by anyone but the NHS. The rise of the internet and social media presents new challenges to its enforcement and raises questions about unintended consequences for patients being treated for cancer.\n\nThrough anonymous surveys, this study aims to understand how patients, healthcare professionals and industry professionals perceive technological changes and their implications for online and social media cancer care information, as well as highlight opportunities for safe and ethical modernisation.",[144,145,26,146,88],"Cancer","Cancer (Active Cancer, Meaning Not Being Cancer Free), of Any Stage and Involving Any Treatment\u002FCare Regimen; i.e. Curative, Life-extending, or Palliative","Cancer (With or Without Metastasis)","2026-05-07",{"date":149,"type":39},"2026-05-13",{"date":151,"type":39},"2026-01-09",{"date":153,"type":20},"2026-05-30",{"name":155,"class":46},"Royal Cornwall Hospitals Trust",{"id":157,"slug":158,"hasResults":11,"nctId":159,"briefTitle":160,"officialTitle":161,"acronym":162,"eligibilityCriteria":163,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":164,"targetDuration":165,"studyType":59,"phases":4,"briefSummary":166,"conditions":167,"keywords":170,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":175,"lastUpdatePostDateStruct":176,"startDateStruct":178,"completionDateStruct":180,"leadSponsor":182,"locationsCount":184},"100626286","wellspan-thrive-cancer-qol-study-100626286","NCT07433660","WellSpan-THRIVE Cancer QOL Study","WellSpan Study of Tracking Health and Resilience to Improve the Vitality of Individuals Experiencing Cancer [WellSpan-THRIVE]","THRIVE","Inclusion Criteria:\n\n* Age 18 years and above\n* Primary cancer diagnosis (newly diagnosed within the past 6 months)\n* Able to sign informed consent.\n\nExclusion Criteria:\n\n* Patients with age\\\u003C18 years,\n* Patients with primary non-melanoma skin, neurological malignancies (Brain or brain metastases), and primary hematological malignancies.\n* Patients with severe cognitive impairment, unable to sign informed consent or unable to complete quality of life questionnaire.\n* Patients with life expectancy of \\\u003C90 days, in the opinion of treating investigator.",{"count":57,"type":20},"24 Months","Cancer affects millions of people worldwide and can significantly impact not only survival, but also day-to-day quality of life. Treatments such as surgery, chemotherapy, and radiation can cause side effects like fatigue, pain, and neuropathy, which may affect physical function, emotional well-being, and social relationships. While many studies have examined factors that influence quality of life; such as age, type and stage of cancer, and treatment-related symptoms; there is still a need for tools that more fully reflect patients' lived experiences.\n\nThis study aims to develop and implement a patient-centered quality of life (QOL) survey designed specifically for individuals with cancer. By directly involving patients in sharing what matters most to them, the survey seeks to provide a more complete and accurate understanding of how cancer and its treatment affect daily life. The results will help patients, families, and healthcare providers better identify needs, guide supportive care, and improve overall well-being throughout the cancer journey.",[145,26,146,168,169,88],"Cancer - Ovarian","Cancer Abdomen",[144,171,172,173,174],"Quality of Life","QOL","Registry","Patient","2026-02-26",{"date":177,"type":39},"2026-03-02",{"date":179,"type":20},"2026-02",{"date":181,"type":20},"2031-12",{"name":183,"class":46},"WellSpan Health",5,{"id":186,"slug":187,"hasResults":11,"nctId":188,"briefTitle":189,"officialTitle":190,"acronym":191,"eligibilityCriteria":192,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":193,"targetDuration":4,"studyType":21,"phases":195,"briefSummary":196,"conditions":197,"keywords":199,"overallStatus":201,"whyStopped":4,"lastUpdateSubmitDate":202,"lastUpdatePostDateStruct":203,"startDateStruct":205,"completionDateStruct":207,"leadSponsor":209,"locationsCount":4},"100621236","comparative-effectiveness-of-verbal-instruction-versus-simulation-video-education-among-cancer-patients-undergoing-radiation-therapy-100621236","NCT07367997","Comparative Effectiveness of Verbal Instruction Versus Simulation Video Education Among Cancer Patients Undergoing Radiation Therapy","Comparative Effectiveness of Verbal Instruction Versus Simulation Video Education Among Cancer Patients Undergoing Radiation Therapy in Lower Middle Income Country Centre: A Randomized Controlled Trial","CARE-RT","Inclusion Criteria:\n\n* Diagnosed with cancer and scheduled for radiation therapy at Tomotherapy unit of Cyber knife and Tomotherapy Centre of JPMC.\n* Fluent in Urdu.\n* No prior experience with radiation therapy.\n* Must have smart phone\n\nExclusion Criteria:\n\nPatients who either refused consent or were ineligible based on the study's inclusion criteria.",{"count":194,"type":20},100,[114],"The goal of this Randomized Controlled Trial is to compare the effectiveness of radiotherapy-specific, physician-led educational videos introduced before the initial Radiation Therapy consultation .\n\nThe primary objective is to assess the impact on patient-reported knowledge of RT, with secondary objectives including assessment of patient-reported anxiety and satisfaction with the educational process.\n\nPatients will be randomly assigned to two groups.\n\n1. Video Group - Patients will receive a WhatsApp message containing the educational video prior to their consultation.\n2. Verbal Instruction Group - Patients will receive standard verbal education from a radiation oncologist during their consultation.\n\nThe participants will fill Pre and post intervention questionnaire forms",[26,198],"Cancer and \u002F or Hematological Malignancy",[200],"Radiation Education","NOT_YET_RECRUITING","2026-01-20",{"date":204,"type":39},"2026-01-26",{"date":206,"type":20},"2026-01",{"date":208,"type":20},"2026-06",{"name":210,"class":211},"Jinnah Postgraduate Medical Centre","OTHER_GOV",{"id":213,"slug":214,"hasResults":11,"nctId":215,"briefTitle":216,"officialTitle":217,"acronym":4,"eligibilityCriteria":218,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":219,"targetDuration":4,"studyType":21,"phases":221,"briefSummary":223,"conditions":224,"keywords":225,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":232,"lastUpdatePostDateStruct":233,"startDateStruct":235,"completionDateStruct":237,"leadSponsor":239,"locationsCount":242},"100617352","phase-1-a-phase-1-study-of-jmt108-in-participants-with-advanced-solid-tumors-100617352","NCT07317505","A Phase 1 Study of JMT108 in Participants With Advanced Solid Tumors","A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of JMT108 Injection in Participants With Advanced Malignant Tumors","Major Inclusion Criteria:\n\n* Age ≥18 years\n* Participants with histologically or cytologically confirmed locally advanced or metastatic solid tumors who are unresponsive or intolerant to all standard of care or have no standard of care available\n* At least one evaluable tumor lesion according to RECIST v1.1.\n* ECOG performance status score ≤2.\n* Expected survival ≥ 3 months\n\nMajor Exclusion Criteria:\n\n* Active central nervous system metastases and\u002For leptomeningeal metastases\n* AEs from prior therapy which have not recovered to Grade ≤1 or baseline as per NCI CTCAE v5.0\n\nPrior therapy\n\n* Any other unapproved investigational drugs or treatments within 4 weeks prior to the first dose of the investigational drug (C1D1).\n* Chemotherapy, radiotherapy, biological therapy, endocrine therapy, targeted therapy, immunotherapy, or other anti-tumor therapies within 4 weeks prior to the first dose of the investigational drug, except in the following situations:\n\n  1. Nitrosoureas or mitomycin C within 6 weeks prior to the first dose of the investigational drug;\n  2. Use of oral fluoropyrimidines and small-molecule targeted drugs within 2 weeks or 5 half-lives of the drug (whichever is longer) prior to the first dose of the investigational drug;\n  3. Use of herbal medicine\u002Fproducts with anti-tumor indications within 2 weeks prior to the first dose of the investigational drug.",{"count":220,"type":20},270,[222],"PHASE1","The goal of this clinical trial is to test JMT108, a type of drug called a bispecific antibody in adult patients with locally advanced or metastatic solid tumors.\n\nThe main questions it aims to answer are:\n\n* To assess the safety and tolerability of JMT108 at increasing doses and determine the dose and schedule to be used in the second part of the study (Phase 1a)\n* To assess effectiveness of JMT108 in participants with locally advanced or metastatic tumors (Phase 1b)\n* To evaluate how quickly JMT108 is metabolized by the body (pharmacokinetics or PK)\n* To evaluate if antibodies to the study drug develop (immunogenicity)\n* To evaluate preliminary efficacy to the drug\n* To explore the pharmacodynamic (PD) characteristics of JMT108\n* To explore the correlation between biomarker levels and preliminary efficacy\n\nParticipants will:\n\n* Provide written informed consent\n* Undergo screening tests to ensure they are eligible for study treatment\n* Attend all required study visits and receive JMT108 by intravenous injection every 2 weeks until the study doctor determines study treatment should be stopped, based on how well a participant is doing on treatment\n* Be followed for progression every 3 months for up to 2 years",[144,26],[65,226,227,228,229,230,231],"solid tumors","advanced malignant","colorectal cancer","hepatocellular cancer","gastric cancer","melanoma","2026-01-19",{"date":234,"type":39},"2026-01-21",{"date":236,"type":39},"2025-12-02",{"date":238,"type":20},"2029-09",{"name":240,"class":241},"Conjupro Biotherapeutics, Inc.","INDUSTRY",3,{"id":244,"slug":245,"hasResults":11,"nctId":246,"briefTitle":247,"officialTitle":247,"acronym":248,"eligibilityCriteria":249,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":250,"targetDuration":252,"studyType":59,"phases":4,"briefSummary":253,"conditions":254,"keywords":256,"overallStatus":201,"whyStopped":4,"lastUpdateSubmitDate":264,"lastUpdatePostDateStruct":265,"startDateStruct":267,"completionDateStruct":269,"leadSponsor":271,"locationsCount":4},"100608238","immune-adverse-events-registry-in-onco-hematologic-patients-treated-with-immunotherapy-100608238","NCT07198958","Immune Adverse Events Registry in Onco-Hematologic Patients Treated With Immunotherapy","MITOX","Inclusion Criteria:\n\n* Any male or female patient (≥18 years old) with diagnosis of solid or hematologic tumor scheduled to begin immunotherapy treatment (prospective)\n* Any male or female patient (≥18 years old) with diagnosis of solid or hematologic tumor already in treatment with immunotherapy with development of irAEs (retro\u002Fprospective)\n* Any male or female patient (≥18 years old) with diagnosis of solid or hematologic neoplasm previously treated with immunotherapy and history of irAEs (retrospective)\n* Patients able to understand and sing an informed consent form (prospective group)\n\nExclusion Criteria:\n\n* Patients \\\u003C 18 years of age\n* Patients with uncertain diagnosis of solid or hematologic tumor\n* Patients not eligible for any clinical reason for immunotherapy\n* Patients unable to understand or sign an informed consent form",{"count":251,"type":20},500,"20 Years","Immunotherapy is a therapeutic strategy aimed at inducing the immune system to identify and combat cancer cells and, alongside the evident clinical success observed in many patients, a specific toxicity profile has emerged, associated with the modulation of the immune system achieved with this type of drugs, known as Immune-Related Adverse Events (irAEs). irAEs encompass a highly heterogeneous spectrum of autoimmune manifestations that can potentially involve any organ or system, occurring in \\~ 80% of patients treated with anti-CTLA-4 agents and in \\~ 60-70% of patients treated with PD-1\u002FPD-L1 inhibitors. However, severe (grade 3-4) irAEs affect only \\~ 15% of patients treated with CTLA-4 inhibitors and \\~ 5-10% of patients receiving anti-PD-1\u002FPD-L1 agents, with a mortality rate ranging from 0.36% to 1.23%. The main characteristic of irAEs is their unpredictability in terms of time of onset, severity and responsiveness to immunosuppressive agents. Therefore, the management of irAEs often requires clever interpretation of clinical symptoms, proper choice of laboratory tests and imaging tools, and ability to perform differential diagnosis with other condition associated to tumour itself or to unrelated concomitant events (i.e., infections). Although international societies (i.e.; ESMO) have provided detailed guidelines for the management of irAEs or algorithms for the administration of ICI in patients with pre-existing autoimmune disease, they are sometimes difficult to be applied to certain complex situations. Furthermore, given the scarcity of data from clinical trials, some of these recommendations are mainly based on highly heterogeneous patients' population included in relatively small real world studies. Therefore, recommendations should always be adapted to specific clinical conditions and challenges. Studies investigating these aspects have particularly focused on the autoimmune antibody response, correlating its positivity in various ways with clinical outcomes. However, the results across different studies are not consistent. Moreover, additional prospective data are needed to confirm which information can guide the management of irAEs in order to optimize therapy and improve prognosis without negatively impacting oncological outcomes. The adoption of a therapeutic strategy tailored to irAEs is essential for improving both the immunological and oncological prognosis of patients affected by this group of manifestations. A prospective and cross-sectional observational approach to study irAEs is fundamental to the development of such therapeutic innovation. This study approach must be based not only on monitoring patients who have already developed irAEs but also on profiling patients even before the development of irAEs to determine which factors are associated with this group of pathologies and the different characteristics they may assume once they arise. The protocol will be based on the retrospective acquisition of data concerning the clinical history of the patients involved, from birth until recruitment into the study, and the prospective recording of information regarding the disease characteristics (both immuno-rheumatological and oncological) and the subsequent evolution of the clinical picture. Study procedures will take place during visits scheduled as part of routine clinical practice and will include the collection of data-clinical, laboratory, and imaging-related to the patient's oncological disease and irAEs, the characteristics of the diagnostic-therapeutic procedures performed, and the subsequent immuno-oncological outcomes. All patients scheduled to begin immunotherapy treatment will be enrolled in the study, as well as those who have developed irAEs without being enrolled prior to the onset of immuno-mediated manifestations. Enrolled patients who do not develop irAEs will be considered as the control group, providing essential information on risk profiling for the development of irAEs.",[144,255,26,146],"Cancer (Colon Cancer, Breast Cancer, Lymphoma, Chronic Lymphoma Leukemia, Multiple Myeloma)",[257,258,144,259,260,261,262,263],"Immunotherapy","Adverse Events","Immune-Related Adverse Events","irAEs","PD-1\u002FPD-L1 inhibitors","anti-CTLA-4 agents","ICI","2025-09-22",{"date":266,"type":39},"2025-09-30",{"date":268,"type":20},"2025-10-01",{"date":270,"type":20},"2045-09",{"name":272,"class":46},"IRCCS San Raffaele",{"id":274,"slug":275,"hasResults":11,"nctId":276,"briefTitle":277,"officialTitle":278,"acronym":4,"eligibilityCriteria":279,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":280,"targetDuration":4,"studyType":21,"phases":282,"briefSummary":284,"conditions":285,"keywords":290,"overallStatus":201,"whyStopped":4,"lastUpdateSubmitDate":295,"lastUpdatePostDateStruct":296,"startDateStruct":298,"completionDateStruct":300,"leadSponsor":302,"locationsCount":4},"100604997","phase-2-n-acetylcysteine-roles-in-preserving-renal-function-measured-by-urinary-kim-1-kidney-injury-molecule-1-and-serum-creatinine-on-cancer-patients-with-cisplatin-based-chemotherapy-a-randomized-placebo-controlled-trial-100604997","NCT07156786","N-Acetylcysteine Roles in Preserving Renal Function Measured by Urinary KIM-1 (Kidney Injury Molecule-1) and Serum Creatinine on Cancer Patients With Cisplatin Based Chemotherapy: A Randomized Placebo-Controlled Trial","N-Acetylcysteine Role on Urinary KIM-1 and Serum Creatinine Level in Cancer Patient With Cisplatin Based Chemotherapy","Inclusion Criteria:\n\n* Patient with cancer\u002F malignancy proven by histopathological examination\n* Patient with GFR ≥60 ml\u002Fmins\u002F1,73 m²\n* Patient with normal complete blood count and liver function test result\n* Patient with good performance status (Karnofsky score ≥80)\n* Patients with cisplatin based chemotherapy\n\nExclusion Criteria:\n\n* Patient that can not tolerate N-Acetylcysteine usage\n* Patient with history of hypersensitivity to N-Acetylcysteine\n* Patient that given other potentially nephrotoxic drug, such as furosemide, non-steroidal anti-infammatory drugs, aminoglycosides, amphotericin B, cephalosporine\n* Patient that given other chemotherapy drug, such as permetrexed, ifosfamide, gemcitabin, bevacizumab, cetuxsimab\n* Patient with history of malignant or uncontrolled hypertension\n* patient with congestive heart failure, kidney structure abnormality, and acute infection\n* Pregnant or lactating women\n* Patient refusing to participate in the research",{"count":281,"type":20},72,[23,283],"PHASE3","The goal of this clinical trial is to learn if N-Acetylcysteine drug works to protect kidney function in adults patient with cancer. Kidney function will be measured by laboratory parameter using urine sample (KIM-1 urine) and blood sample (serum creatinine). The main questions it aims to answer are:\n\n1. Does N-Acetylcysteine lower the level of KIM-1 (Kidney Injury Molecule) in patients urine indicating kidney function protection?\n2. Does N-Acetylcysteine lower the level of creatinine in patients blood indicating kidney function protection?\n\nParticipants will:\n\n1. Had their blood and urine sample taken before taking the drugs (N-Acetylcysteine or placebo)\n2. Underwent cisplatin based chemotherapy\n3. Taken placebo or N-Acetylcysteine for seven days (1 day before chemotherapy, on the chemotherapy day, and 5 days after chemotherapy)\n4. Had their blood and urine sample taken twice after taking the drugs (1 week and 3 weeks after chemotherapy)\n5. Had their symptoms monitor during and after taking the drugs. Every possible side effect, hospitalization, or death will be recorded.",[286,287,26,288,289],"Kidney Function Issue","Acute Kidney Injury","Kidney Function Tests","Acetylcysteine Adverse Reaction",[291,292,293,294],"kidney injury molecule 1","KIM-1","Creatinine","N-Acetylcysteine","2025-09-13",{"date":297,"type":39},"2025-09-19",{"date":299,"type":20},"2025-09-15",{"date":301,"type":20},"2027-08-31",{"name":303,"class":46},"Fakultas Kedokteran Universitas Indonesia",{"id":305,"slug":306,"hasResults":11,"nctId":307,"briefTitle":308,"officialTitle":308,"acronym":309,"eligibilityCriteria":310,"healthyVolunteers":11,"sex":16,"minAge":311,"maxAge":312,"enrollmentInfo":313,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":315,"conditions":316,"keywords":341,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":345,"lastUpdatePostDateStruct":346,"startDateStruct":348,"completionDateStruct":350,"leadSponsor":352,"locationsCount":242},"100599630","cardiovascular-risk-in-children-with-chronic-conditions-study-100599630","NCT07086989","Cardiovascular Risk in Children With Chronic Conditions Study","CR3C","Inclusion criteria:\n\n1. Individuals aged between 6 and 25 years;\n2. Diagnosed with a chronic childhood condition\u002Fdisease associated with an increased risk of early cardiovascular disease;\n3. Provided informed consent (if over 18 years old) or had informed consent provided by their legal guardian (if under 18 years old) following appropriate information about the study.\n\nChronic childhood conditions\u002Fdiseases associated with increased risk of early cardiovascular disease are defined according to the 2019 American Heart Association recommendations (https:\u002F\u002Fdoi.org\u002F10.1161\u002FCIR.0000000000000618), as well as other conditions\u002Fdiseases for which at least two large-scale epidemiological studies have demonstrated an increased risk of cardiovascular disease.\n\nExclusion criteria:\n\n1. Severe intellectual and developmental disability;\n2. Decompensated heart failure;\n3. Severe primary immunodeficiency;\n4. Ongoing intravenous chemotherapy;\n5. Infectious diseases posing a public health risk; or\n6. History of regular alcohol or drug use.","6 Years","25 Years",{"count":314,"type":20},300,"Children living with chronic health conditions face a higher risk of developing cardiovascular diseases than their peers, largely due to the accelerated aging of the heart and blood vessels. Although experts recognize this elevated risk and recommend close monitoring and early intervention, the underlying mechanisms driving this phenomenon remain poorly understood. At present, no effective interventions specifically target its root causes.\n\nRecent research shows that both large blood vessels (such as the carotid artery) and small vessels (such as those in the retina) can display early signs of damage decades before clinically apparent heart or vascular disease emerges. This accelerated vascular aging can result from multiple factors - including disease-related processes such as persistent inflammation and metabolic disturbances, treatment-related effects such as chemotherapy or long-term steroid use, and lifestyle changes associated with chronic illness, such as reduced physical activity and altered eating habits. However, it is still unclear how these factors influence the development and progression of vascular changes in children as they grow. Importantly, these changes can be monitored through non-invasive methods, offering a unique opportunity to study at-risk patients many years before overt cardiovascular disease develops.\n\nIdentifying these early changes may enable us to detect and track individuals at heightened risk well in advance of clinical disease. This study aims to deepen our understanding of the causes of increased cardiovascular risk in children with chronic conditions and to lay the groundwork for earlier, more targeted prevention strategies.",[317,318,319,320,321,322,323,324,325,326,327,26,328,329,330,331,332,333,334,335,336,337,338,339,340],"Kidney Transplant","Familial Hypercholesterolaemia","Type 1 Diabetes Mellitus (T1DM)","Type 2 Diabetes Mellitus (T2DM)","Chronic Kidney Disease","Kawasaki Disease","Liver Transplant","Obesity and Overweight","Hypertension","Coarctation of Aorta","Bone Marrow Transplant","Leukemia","Lymphoma","Lipoprotein(a)","Aorta Stenosis","Non Alcoholic Fatty Liver Disease","Dyslipaemia","White Coat Hypertension","Pulmonary Hypertension","Juvenile Idiopahtic Arthritis","Systemic Lupus Erthematosus","Inflammatory Bowel Disease (IBD)","HIV Infection","Transposition of Great Arteries",[342,343,344],"cardiovascular risk","vasculature","children with chronic conditions","2025-08-04",{"date":347,"type":39},"2025-08-08",{"date":349,"type":39},"2025-04-01",{"date":351,"type":20},"2029-01-31",{"name":353,"class":46},"Semmelweis University",{"id":355,"slug":356,"hasResults":11,"nctId":357,"briefTitle":358,"officialTitle":359,"acronym":4,"eligibilityCriteria":360,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":361,"targetDuration":4,"studyType":21,"phases":363,"briefSummary":364,"conditions":365,"keywords":367,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":375,"lastUpdatePostDateStruct":376,"startDateStruct":378,"completionDateStruct":380,"leadSponsor":382,"locationsCount":47},"100601012","salutare-one-referral-software-impact-on-multi-disciplinary-team-mdt-meetings-effectiveness-and-safety-100601012","NCT07104955","Salutare One Referral Software Impact on Multi-Disciplinary Team (MDT) Meetings Effectiveness and Safety","Single Cohort Before and After Mixed-methods Prospective Study to Investigate the Impact of the Salutare One Referral Software on Patient Outcomes, Safety and Effectiveness of Multi-Disciplinary Team (MDT) Meetings","Inclusion Criteria:\n\n* MDT meeting Panel Members, Coordinators and staff submitting MDT referrals will take part in this study.\n\nExclusion Criteria:\n\n* MDT meeting Panel Members, Coordinators and staff submitting MDT referrals who are unwilling or unable to take part in the study.",{"count":362,"type":20},40,[114],"Multi-Disciplinary Team (MDT) meetings are crucial for planning patient care in the National Health Service (NHS), but they can be time-consuming and sometimes lack complete patient information. This can lead to delays in treatment decisions, potentially incomplete care plans, or the need to repeatedly discuss the same patient cases.\n\nThis study aims to test a new software called Salutare One Referral. One Referral is designed to make these meetings more efficient and effective. We want to see if this software can help healthcare staff prepare MDT referral information more easily and facilitate a more informed MDT discussion, which could lead to better patient care. If successful, this could help improve how MDTs operate across the NHS.",[26,366],"Sarcoma",[368,369,370,371,372,373,374],"digital health","digital health intervention","multi-disciplinary team meeting","MDT","digital health technology","referral","software","2025-08-01",{"date":377,"type":39},"2025-08-05",{"date":379,"type":39},"2025-07-31",{"date":381,"type":20},"2026-07-19",{"name":383,"class":241},"Salutare Group Ltd."]